Albuked Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical use of albumin in shock management, reliance on plasma derived albumin, rising incidence of liver disorders, hospital based critical care growth, established efficacy in fluid management.

The growth in the forecast period can be attributed to demand for safer non plasma products, increasing burn and trauma cases, expansion of recombinant protein manufacturing, rising ICU admissions, regulatory support for synthetic proteins. Major trends in the forecast period include growing adoption of recombinant albumin, shift away from plasma derived albumin, rising use in critical care settings, increasing preference for synthetic therapeutics, expansion of intravenous protein therapies.

The increasing incidence of liver disorders is expected to drive the growth of the Albuked market in the coming years. Liver disorders include a wide range of conditions that impair liver function, such as hepatitis, cirrhosis, fatty liver disease, and autoimmune liver diseases. The rise in liver-related conditions is largely associated with factors including excessive alcohol intake, obesity, viral infections, exposure to toxins, and genetic factors that negatively impact liver health. Albuked is used in the management of liver disorders, particularly in cases of acute liver failure, where it helps maintain plasma colloid osmotic pressure and bind excess bilirubin in patients experiencing rapid loss of liver function, potentially reducing the risk of severe complications such as hepatic coma. For example, in September 2023, according to the American Liver Foundation, a US-based non-profit organization, more than 100 million people in the United States were affected by some form of liver disease. Of these, approximately 4.5 million adults, or 1.8%, had received a formal diagnosis, while an estimated 80-100 million adults were living with fatty liver disease, many of whom were unaware of their condition. Additionally, in August 2023, according to the Journal of Hepatology, a Switzerland-based peer-reviewed medical journal, liver disease accounts for more than 2 million deaths annually, representing about 4% of all deaths worldwide, or roughly one in every 25 deaths. Notably, nearly one-third of these deaths occur among women, and liver cancer alone is responsible for an estimated 600,000 to 900,000 deaths each year. Therefore, the growing burden of liver disorders is contributing to the expansion of the Albuked market.

A key trend shaping the Albuked market is the focus on developing advanced therapies such as human albumin injection treatments to address critical medical conditions. Human albumin injection therapy involves the clinical use of human serum albumin, a plasma-derived protein, to manage conditions including hypoalbuminemia, liver cirrhosis, trauma, severe burns, and situations requiring fluid resuscitation during surgical procedures. For instance, in July 2023, Grifols S.A., a Spain-based producer of plasma-derived medicines, announced the completion of a phase 3 clinical study under the PRECIOSA program to evaluate the potential of long-term albumin-based therapy using its Albutein product. This study is intended to assess whether such treatment can extend survival in patients with decompensated cirrhosis and ascites while they await liver transplantation.

In June 2023, Kedrion Biopharma, a US-based biopharmaceutical company, entered into a partnership with Bio Products Laboratory (BPL) to expand access to plasma-derived therapies in China. Through this collaboration, Kedrion Biopharma and BPL aim to increase the availability of human albumin products within the Chinese market, supporting broader patient access to essential plasma-based treatments. Bio Products Laboratory is a UK-based pharmaceutical company specializing in the manufacture and supply of plasma-derived products for healthcare providers and patients.

Major companies operating in the albuked market are Kedrion Biopharma Inc.

North America was the largest region in the albuked market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the albuked market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the albuked market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the albuked market by increasing costs of imported bioprocessing equipment and recombinant raw materials. This has affected production economics for synthetic albumin formulations, particularly in Asia Pacific and Europe. Hospital procurement costs have risen due to higher manufacturing inputs. However, tariffs are supporting local biomanufacturing investments and encouraging domestic production of recombinant albumin therapies.

The albuked market research report is one of a series of new reports that provides albuked market statistics, including albuked industry global market size, regional shares, competitors with a albuked market share, detailed albuked market segments, market trends and opportunities, and any further data you may need to thrive in the albuked industry. This albuked market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Albuked is a recombinant human albumin-based therapeutic protein primarily used to treat hypoalbuminemia, a condition characterized by abnormally low levels of albumin in the blood. It is produced using genetic engineering techniques and is applied in various medical conditions, including liver cirrhosis, nephrotic syndrome, and burns. Albuked functions by restoring albumin levels in the bloodstream, helping to maintain fluid balance, enhance circulation, and reduce complications associated with protein deficiencies. As a synthetic product, it serves as an alternative to plasma-derived albumin and is typically administered intravenously under medical supervision.

The main formulation types of Albuked include Albuked 5%, Albuked 25%, Plasbumin-5, and Plasbumin-25. Albuked 5% is a human serum albumin formulation intended for therapeutic use in managing conditions such as hypovolemia and hypoalbuminemia. The indications include hypovolemic shock, hypoproteinemia, acute respiratory distress syndrome (ARDS), cardiopulmonary bypass, and acute liver failure, with packaging sizes available in 50 mL, 250 mL, and 500 mL. The product is distributed through hospitals and clinics as well as retail and specialty pharmacies and is used by end users including adult and geriatric patients.

The albuked market consists of sales of Albuminar-5, Albuminar-25, and Buminate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.